Ruxolitinib Combinations Reduce Spleen Volume in Myelofibrosis
Meeting Coverage > > ASH: Hematology-- Combos with navitoclax or pelabresib caused more clients accomplishing decreases
by Mike Bassett, Staff Writer, MedPage Today December 12, 2023
SAN DIEGO-- Combining the Janus kinase (JAK) inhibitor ruxolitinib (Jakafi) with either navitoclax or pelabresib resulted in more clients with myelofibrosis accomplishing decreases in spleen volume, 2 stage III research studies revealed.
In the TRANSFORM-1 trial, the mix of the BCL-XL/BCL -2 inhibitor navitoclax and ruxolitinib doubled the variety of clients who accomplished a 35% or higher decrease in spleen volume (SVR35) by week 24 (63.2% vs 31.5%, P< 0.0001) compared to clients who...